Regeneron Pharmaceuticals REGN reported its Q3 earnings results on Thursday, November 3, 2022 at 06:30 AM.
Here's what investors need to know about the announcement.
Earnings
Regeneron Pharmaceuticals beat estimated earnings by 17.02%, reporting an EPS of $11.14 versus an estimate of $9.52.
Revenue was down $517.00 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.23 which was followed by a 1.02% increase in the share price the next day.
Here's a look at Regeneron Pharmaceuticals's past performance:
Quarter | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
---|---|---|---|---|
EPS Estimate | 9.54 | 10.04 | 18.11 | 9.49 |
EPS Actual | 9.77 | 11.49 | 23.72 | 15.37 |
Revenue Estimate | 2.79B | 2.73B | 4.47B | 2.79B |
Revenue Actual | 2.86B | 2.96B | 4.95B | 3.45B |
To track all earnings releases for Regeneron Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.